Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis

NCT06723171 | Suspended Phase 2 FDA Drug

• 1 other identifier: IRX4204Psoriasis201
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to learn if IRX4204 works to treat plaque psoriasis in adults. It will also learn about the safety of IRX4204. The main questions it aims to answer are:

• Does IRX4204 treat plaque psoriasis symptoms?
• Does IRX4204 treat plaque psoriasis symptoms better than someone who is not being treated?
• What medical problems do participants have when taking IRX4204? Researchers will compare IRX4204 to a placebo (a look-alike substance that contains no drug) to see if the drug works to treat mild to moderate plaque psoriasis. Participants will:
• Take IRX4204 every day for 28 days
• Visit the clinic once every week for checkups and tests
• Complete specific assessments about plaque psoriasis and changes to plaques

Conditions

Psoriasis; Plaque Type Psorisis; Plaque Psoriasis

Keywords

RXR; Psoriasis; plaque psoriasis; plaques; mild psoriasis; IRX4204; IO Therapeutics

Outcome Measures

Primary Outcomes (1)

• To evaluate if participants receiving IRX4204 achieve greater reduction in IGA scores when compared to participants receiving placebo

  Percentage of participants achieving an Investigator's Global Assessment (IGA) score of clear (0) or almost clear (1) at Day 28 with at least a 2-grade improvement from Baseline to end of study.

  Baseline (Day 1) to Day 42

Secondary Outcomes (4)

• To evaluate if participants receiving IRX4204 have greater improvement in participant reported outcomes when compared to participants receiving placebo

  from Baseline (Day 1) to Day 28

• To evaluate if participants receiving IRX4204 experience a greater reduction in affected Body Surface Area when compared to participants receiving placebo

  from Baseline (Day 1) to Day 28

• To evaluate if a greater proportion of participants receiving IRX4204 achieve PASI50, PASI75 and PASI90 when compared to participants receiving placebo

  from Baseline (Day 1) to End of Study (Day 42)

• To evaluate if participants receiving IRX4204 achieve greater improvement from baseline in disease and symptom severity as measured by the Psoriasis Area and Severity Index (PASI).

  from Baseline (Day 1) to End of Treatment (Day 28)

Other Outcomes (1)

• Incidence of Treatment Emergent and Serious Adverse Events

  from Baseline (Day 1) to End of Study (Day 42)

Study Arms (2)

Treatment

ACTIVE COMPARATOR

IRX4204

Drug: IRX4204

Placebo

PLACEBO COMPARATOR

Placebo

Other: Placebo

Interventions

IRX4204 DRUG

Active Treatment

Also known as: IRX4204Psoriasis, NRX194204

Treatment

Placebo OTHER

Placebo

Placebo

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• At least 18 years of age
• Have a diagnosis of plaque psoriasis (with or without psoriatic arthritis) for at least 6 months before the first administration of study treatment
• Meet the following disease severity criteria for moderate to severe plaque psoriasis at Screening and Baseline visits:
• IGA Score of 3 or 4 AND
• Total affected body surface area of \>3 to 10% for moderate and 10% to 15% for severe psoriasis
• Excludes participants with scalp only plaques
• Be inadequately controlled with or intolerant of at least one prior topical therapy including but not limited to: corticosteroids, retinoids, vitamin D, vitamin D/steroid and retinoid/steroid combinations, tacrolimus, pimecrolimus, anthralin/dithranol, coal tar preparations, tapinarof, roflumilast for the treatment of psoriasis at both Screening and Baseline visits
• In the opinion of the Investigator, be a candidate for phototherapy or systemic treatment for psoriasis
• Completed appropriate washouts for prior treatments for psoriasis
• Be considered, in the opinion of the Investigator, suitable candidates for RXR agonist therapy
• Women participants of childbearing potential (WOCBP) (see Section 8.1.10) or sexually active male participants with partners of childbearing potential agree to practice a highly effective method of contraception (failure rate of \< 1% per year when used consistently and correctly; see Section 8.1.10.1) prior to receiving, while receiving, and for at least 6 months after receiving the last administration of study intervention
• WOCBP must have a negative highly sensitive serum beta-human chorionic gonadotropic (b-hCG) pregnancy test at Screening and confirmed at Baseline prior to receiving the first administration of study drug
• WOCBP must agree not to donate eggs (ova, oocytes) or freeze for future and males must agree not to donate sperm for the purpose of reproduction for at least 6 months after receiving the last administration of study intervention.
• Female participants must agree to not breastfeed while enrolled in this study and within 6 months after the last dose of study intervention
• Sign an informed consent form (ICF) indicating that the participant understands the purpose of, and procedures required for, the study and is willing to participate in the study

You may not qualify if:

• Has more than 15% of total body surface area affected by psoriasis plaques
• Has a non-plaque form of psoriasis (e.g., erythrodermic, guttate, or pustular) at Screening or at time of randomization
• Has current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta-blockers, calcium channel blockers, or lithium)
• Has confounding diagnoses including but not limited to palmoplantar pustulosis, eczematous dermatitis, contact/irritant dermatitis, acquired keratoderma
• Has received within 12 weeks of the first dose (Day 1) any prior biologic (or biosimilars of) for the treatment of psoriasis, psoriatic arthritis, or any other indications that could impact the assessment of psoriasis. Prior biologic therapy includes but is not limited to TNF-inhibitors, IL-17 inhibitors, IL-12/23 inhibitors, IL-23 inhibitors
• Has received within 4 weeks of the first dose (Day 1) any systemic immunosuppressives for the treatment of psoriasis or psoriatic arthritis, or any other indications that could impact the assessment of psoriasis, Phototherapy or narrow band laser (e.g., Excimer or XTRAC), lithium, antimalarials, or intramuscular (IM) gold. Systemic immunosuppressive therapy includes but is not limited to methotrexate, azathioprine, cyclosporine, JAK/TYK pathway inhibitors, 6-thioguanine, mercaptopurine, mycophenolate mofetil, tacrolimus, acitretin, or anakinra
• Has received within 2 weeks of the first dose (Day 1) any topical medications for psoriasis or other conditions that could impact assessment of psoriasis, including but not limited to topical corticosteroids, retinoids, vitamin D analogs, combinations of calcipotriene and topical corticosteroids, tacrolimus, pimecrolimus, anthralin/dithranol, coal tar preparations, PDE4 inhibitors (e.g. crisaborole), or other topicals used for the treatment of psoriasis (tapinarof, roflumilast etc.)
• Has received within 12 weeks or 5 half-lives (whichever is longer) of the first dose (Day 1) other biologic therapy or experimental antibody, any agent that modulates T-cells (e.g., natalizumab, abatacept etc.)
• Has received within 4 weeks or 5 half-lives (whichever is longer) of the first dose (Day 1) any other experimental systemic therapy for any indication
• Is currently enrolled in another study using an investigational agent or procedure
• Has evidence of skin conditions that could interfere with clinical assessments of psoriasis (e.g. eczema, seborrheic dermatitis, or pityriasis rosea)
• Has a current history of severe, uncontrolled or progressive systemic medical conditions including renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
• Has unstable cardiovascular disease, defined as a recent clinical deterioration in the last 3 months (e.g., unstable angina, atrial fibrillation) or a cardiac hospitalization within the last 3 months
• Currently has a known malignancy or has a history of malignancy within 5 years before screening with the exception of non-melanoma skin cancer curatively treated with no evidence of recurrence for at least 3 months before the first study drug administration or cervical carcinoma in situ of the cervix that has been treated with no evidence of recurrence for at least 3 years before the first study drug administration
• Has a history of lymphoproliferative disease, including lymphoma, leukemia, monoclonal gammopathy, or signs/symptoms suggestive of possible lymphoproliferative disease

Sponsors & Collaborators

• Io Therapeutics: lead

Study Sites (1)

Not posted

Webster, Texas, 77598, United States

Location

MeSH Terms

Conditions

Psoriasis; Plaque, Amyloid

Interventions

IRX4204; AGN 194204

Condition Hierarchy (Ancestors)

Skin Diseases, Papulosquamous; Skin Diseases; Skin and Connective Tissue Diseases; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Double-blind, placebo controlled

Study Record Dates

• First Submitted: December 4, 2024
• First Posted: December 9, 2024
• Study Start: March 1, 2026
• Primary Completion: March 1, 2026
• Study Completion: April 1, 2026
• Last Updated: March 3, 2026

Record last verified: 2025-04

Locations

US (1)